UBS Group
NAGE

UBS Group’s Niagen Bioscience NAGE Stock Holding History

UBS Group’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.2M Sell
1,405,531
-6,211
-0.4% -$33.5K ﹤0.01% 3835
2025
Q4 		$8.98M Buy
1,411,742
+215,645
+18% +$1.5M ﹤0.01% 3404
2025
Q3 		$11.2M Buy
1,196,097
+1,110,441
+1,296% +$11.2M ﹤0.01% 3175
2025
Q2 		$1.23M Buy
85,656
+30,520
+55% +$301K ﹤0.01% 5258
2025
Q1 		$380K Buy
55,136
+10,663
+24% +$67K ﹤0.01% 6076
2024
Q4 		$236K Sell
44,473
-14,416
-24% -$78.9K ﹤0.01% 6353
2024
Q3 		$215K Sell
58,889
-80,857
-58% -$254K ﹤0.01% 5822
2024
Q2 		$382K Buy
139,746
+119,723
+598% +$401K ﹤0.01% 5207
2024
Q1 		$69.7K Buy
20,023
+18,570
+1,278% +$34.4K ﹤0.01% 6363
2023
Q4 		$2.08K Buy
1,453
+394
+37% +$549 ﹤0.01% 8170
2023
Q3 		$1.55K Sell
1,059
-5,467
-84% -$8.54K ﹤0.01% 7900
2023
Q2 		$10.2K Sell
6,526
-11,089
-63% -$16.5K ﹤0.01% 7147
2023
Q1 		$27K Buy
17,615
+206
+1% +$367 ﹤0.01% 6869
2022
Q4 		$29.2K Sell
17,409
-6,500
-27% -$10.3K ﹤0.01% 7264
2022
Q3 		$29K Sell
23,909
-516
-2% -$830 ﹤0.01% 6932
2022
Q2 		$41K Buy
24,425
+2,750
+13% +$5.38K ﹤0.01% 6078
2022
Q1 		$53K Sell
21,675
-33,334
-61% -$91.1K ﹤0.01% 6447
2021
Q4 		$206K Buy
55,009
+2,389
+5% +$12.9K ﹤0.01% 5663
2021
Q3 		$330K Sell
52,620
-46,801
-47% -$386K ﹤0.01% 4981
2021
Q2 		$980K Buy
99,421
+48,617
+96% +$424K ﹤0.01% 4193
2021
Q1 		$474K Sell
50,804
-101,490
-67% -$804K ﹤0.01% 4913
2020
Q4 		$731K Buy
152,294
+1,694
+1% +$8.26K ﹤0.01% 4269
2020
Q3 		$604K Sell
150,600
-51,281
-25% -$247K ﹤0.01% 4029
2020
Q2 		$926K Sell
201,881
-18,538
-8% -$83K ﹤0.01% 3577
2020
Q1 		$719K Sell
220,419
-17,505
-7% -$67.2K ﹤0.01% 3651
2019
Q4 		$1.02M Buy
237,924
+27,971
+13% +$99.4K ﹤0.01% 4192
2019
Q3 		$826K Buy
209,953
+16,264
+8% +$69.4K ﹤0.01% 4133
2019
Q2 		$900K Sell
193,689
-1,261
-0.6% -$5.38K ﹤0.01% 3830
2019
Q1 		$817K Buy
194,950
+42,607
+28% +$154K ﹤0.01% 3726
2018
Q4 		$523K Buy
152,343
+7,281
+5% +$25.3K ﹤0.01% 4230
2018
Q3 		$623K Sell
145,062
-642
-0.4% -$2.76K ﹤0.01% 4256
2018
Q2 		$541K Buy
145,704
+24,292
+20% +$92.3K ﹤0.01% 4258
2018
Q1 		$510K Buy
121,412
+58,848
+94% +$308K ﹤0.01% 4187
2017
Q4 		$368K Buy
62,564
+27,564
+79% +$149K ﹤0.01% 4507
2017
Q3 		$151K Buy
35,000
+21,691
+163% +$79.3K ﹤0.01% 5044
2017
Q2 		$51K Sell
13,309
-6,174
-32% -$19.6K ﹤0.01% 5627
2017
Q1 		$52K Buy
19,483
+182
+0.9% +$516 ﹤0.01% 5500
2016
Q4 		$64K Buy
19,301
+6,301
+48% +$17.1K ﹤0.01% 5634
2016
Q3 		$39K Sell
13,000
-2,932
-18% -$10.8K ﹤0.01% 5715
2016
Q2 		$66K Buy
+15,932
New +$75.4K ﹤0.01% 5318

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's NAGE Position: Q1 2026 in Review

UBS Group reduced its Niagen Bioscience (NAGE) stake by 0.44% in Q1 2026, selling an estimated $33.5K and leaving 1,405,531 shares worth $6.2M. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

UBS Group first reported a position in NAGE in Q2 2016 and has held it in 40 quarters since. The position peaked at $11.2M in Q3 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • UBS Group held 1,405,531 shares of Niagen Bioscience worth $6.2M as of Q1 2026.
  • UBS Group sold 6,211 Niagen Bioscience shares in Q1 2026, an estimated $33.5K.
  • Niagen Bioscience made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3835 holding.
  • UBS Group first reported a position in Niagen Bioscience in Q2 2016 and has held it in 40 quarters since.
  • UBS Group's Niagen Bioscience position peaked at $11.2M in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.